Biotech Firms, Billions at Risk, Lobby States to Limit Generics
Tuesday, January 29, 2013 - 00:01
in Mathematics & Economics
The industry’s lobbying effort could blunt new competition to its products and reduce the savings anticipated in the federal health care overhaul.